crossmark
Risk Factors and Outcomes for Intestinal Carriage of AmpCHyperproducing Enterobacteriaceae in Intensive Care Unit Patients Simon Poignant,a Jérôme Guinard,b Aurélie Guigon,b Laurent Bret,b Didier-Marc Poisson,b Thierry Boulain,a François Barbiera Medical Intensive Care Unita and Department of Microbiology,b La Source Hospital, CHR Orléans, Orléans, France
In a cohort of 1,209 intensive care unit (ICU) patients, the prevalence of intestinal colonization with high-level expressed AmpC cephalosporinase-producing Enterobacteriaceae (HLAC-PE) rose steadily from 2% at admission to 30% in patients with lengths of stay (LOS) exceeding 4 weeks. In multivariate analysis, LOS was the main predictor of carriage acquisition after adjustment on antimicrobial exposure. HLAC-PE infection occurred in 15% of carriers. Carriage and infection were associated with a marked increase in carbapenem consumption.
T
he burden of expanded-spectrum cephalosporin (ESC) resistance in Enterobacteriaceae now represents a daily issue for the management of antimicrobial therapy in intensive care unit (ICU) patients (1, 2). Two distinct enzymatic mechanisms may be involved, namely, plasmid-borne extended-spectrum beta-lactamases (ESBL) and high-level expressed AmpC cephalosporinase (HLAC) (2). The HLAC phenotype results from the mutationinduced derepression of a normally low-level expressed chromosomal blaampC gene or, more rarely, from the horizontal transfer of a plasmid-borne AmpC variant (3). HLAC-producing Enterobacteriaceae (HLAC-PE) currently account for up to 50% of the ESCresistant Enterobacteriaceae responsible for ICU-acquired infections in settings with a high prevalence of ESBL-producing Enterobacteriaceae (ESBL-PE) (4). The intestinal microbiota forms the main reservoir of ESCresistant Enterobacteriaceae in ICU patients (5–7); however, the features of HLAC-PE carriage remain poorly described in this population. Our objectives were to identify the risk factors for HLAC-PE carriage and to appraise its clinical significance in terms of subsequent infections and carbapenem consumption in a large single-center cohort of critically ill patients. This retrospective study was conducted in the 18-bed medicalsurgical ICU of an 1,100-bed teaching hospital in France. During the 3-year study period (2008 to 2010), intestinal carriage of ESCresistant Enterobacteriaceae was routinely screened by rectal swabbing at admission and at weekly intervals afterwards as part of the institutional infection control policy, with implementation of isolation measures in identified carriers. Swabs were discharged in 1 ml of 0.9% saline, and 50 l of the suspension was subsequently plated on a selective medium for ESC-resistant Gram-negative bacilli (chromID ESBL; bioMérieux, Marcy-l’Étoile, France). After overnight incubation at 35°C, colonies were subcultured for identification (API 20E; bioMérieux) and susceptibility testing using the disk diffusion method on Mueller-Hinton agar plates (Bio-Rad, Marnes-la-Coquette, France), in accordance with the French Society of Microbiology guidelines (www.sfm-microbiologie.org). Third-generation cephalosporin -resistant Enterobacteriaceae isolates showing a synergy zone between ESC and clavulanate were categorized as ESBL-PE, while those without synergy and a ⱖ5-mm increase in the ESC inhibition diameter on cloxacillin-supplemented Mueller-Hinton agar (250 mg · ml⫺1) were categorized as HLAC-PE. Isolates producing ESBL and HLAC were classified as ESBL-PE. No
March 2016 Volume 60 Number 3
carbapenem-resistant Enterobacteriaceae were isolated in our ICU during the study period. Patients with a first ICU stay of more than 48 h were included. Variables in the tables were prospectively entered by attending ICU physicians into a local database used for diagnosis and procedures coding, surveillance of ICU-acquired infections, and monitoring of antimicrobial consumption. Additional data on antibiotic exposure were retrospectively extracted from the patients’ medical charts. HLAC-PE carriers were identified in the database of the bacteriology unit. Imported carriage was defined as a positive swab at ICU admission, while acquired carriage was defined as a positive surveillance swab in patients with a negative admission sample. Carriers were assumed to be colonized from the first positive swab to ICU discharge or death. The Institutional Review Board waived the requirement for informed consent (IRB 2015-02). Data are reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statements (8). Carriers and noncarriers were compared using the Student t test or the Mann-Whitney test for continuous variables and the Fischer exact test or the 2 test for categorical variables as appropriate. All tests were two-sided, and P values of ⬍0.05 were considered significant. Statistical analyses were carried out using R 2.15.1 (http://www.r-project.org). A total of 1,209 patients were included (Table 1; see also Fig. S1 in the supplemental material). None of them had a history of documented HLAC-PE infection during the hospital stay prior to ICU admission or during a previous hospital stay within the year preceding ICU admission. The 24 patients (2.0%) with imported HLAC-PE carriage had more frequent histories of chronic diseases, hospitalization within the previous year, and surgery within
Received 28 August 2015 Returned for modification 3 October 2015 Accepted 5 December 2015 Accepted manuscript posted online 14 December 2015 Citation Poignant S, Guinard J, Guigon A, Bret L, Poisson D-M, Boulain T, Barbier F. 2016. Risk factors and outcomes for intestinal carriage of AmpC-hyperproducing Enterobacteriaceae in intensive care unit patients. Antimicrob Agents Chemother 60:1883–1887. doi:10.1128/AAC.02101-15. Address correspondence to François Barbier, [email protected]. Supplemental material for this article may be found at http://dx.doi.org/10.1128 /AAC.02101-15. Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Antimicrobial Agents and Chemotherapy
aac.asm.org
1883
Poignant et al.
TABLE 1 Study population and factors associated with intestinal carriage of high-level AmpC cephalosporinase-producing Enterobacteriaceae at intensive care unit admissiona
Variable
All patients (n ⫽ 1,209)
Median age (interquartile range), yr Male gender, no. (%)
Intestinal carriage of HLAC-PE at ICU admission Carriers (n ⫽ 24)
Noncarriers (n ⫽ 1,185)
P value
63 (49–75) 763 (63.1)
68 (51–75) 19 (79.2)
63 (49–74) 744 (62.8)
0.23 0.13
Comorbidities, no. (%) Cardiac Respiratory End-stage renal disease Neurological Liver cirrhosis Malignancies Diabetes mellitus
579 (47.9) 296 (24.5) 23 (1.9) 66 (5.5) 37 (3.1) 123 (10.2) 223 (18.4)
15 (62.5) 12 (50.0) 0 3 (12.5) 2 (8.3) 5 (20.8) 8 (33.3)
564 (47.6) 284 (24.0) 23 (1.9) 63 (5.3) 35 (2.9) 118 (10.0) 215 (18.1)
0.15 0.007 1.0 0.15 0.16 0.07 0.06
Median McCabe score (interquartile range) Hospital stay within the previous year, no. (%) Surgery within the previous month, no. (%)
0 (0–0) 322 (26.6) 13 (1.1)
0 (0–1) 12 (50.0) 2 (8.3)
0 (0–0) 310 (26.2) 11 (1.0)
0.02 0.02 0.02
Admission, no. (%) Transfer Direct
379 (31.4) 830 (68.6)
15 (62.5) 9 (37.5)
364 (30.7) 821 (69.3)
0.002
Type of ICU stay, no. (%) Medical Surgical
1,091 (90.2) 118 (9.8)
20 (83.3) 4 (16.7)
1,071 (90.4) 114 (9.6)
0.28
Median SAPS II at ICU admission (interquartile range) ESBL-PE carriage at ICU admission, no. (%)
41 (29–53) 24 (2.0)
40 (31–43) 2 (8.3)
41 (29–53) 22 (1.8)
0.54 0.08
Main diagnoses of the ICU stay, no. (%) Sepsis Neurological Renal Cardiac Intestinal/hepatic Trauma
648 (53.6) 181 (15.0) 274 (22.7) 205 (16.9) 54 (4.5) 151 (12.5)
12 (50.0) 5 (20.8) 3 (12.5) 3 (12.5) 2 (8.3) 1 (4.2)
636 (53.7) 176 (14.8) 271 (22.9) 202 (17.0) 52 (4.4) 150 (12.6)
0.84 0.39 0.24 0.78 0.29 0.34
Use of life-sustaining therapies, no. (%) Mechanical ventilation Vasopressors Renal replacement therapy
806 (66.7) 580 (48.0) 125 (10.3)
16 (66.7) 7 (29.2) 1 (4.2)
790 (66.7) 573 (48.3) 124 (10.5)
1.0 0.07 0.5
a
HLAC-PE, high-level expressed AmpC-producing Enterobacteriaceae; ICU, intensive care unit; SAPS II, simplified acute physiology score II; ESBL-PE, extended-spectrum-lactamase-producing Enterobacteriaceae.
the previous month and were more often transferred from ward than patients not colonized at admission (Table 1). Enterobacter cloacae accounted for half of the imported HLAC-PE isolates (see Table S1 in the supplemental material). Among the 1,185 patients without HLAC-PE carriage at admission (median ICU length of stay [LOS], 7 days; interquartile range, 4 to 12 days), 107 (8.9%) became colonized during the ICU stay (acquisition rate, 7.7 per 1,000 patient-days). The rate of HLAC-PE carriage increased markedly over time, exceeding 30% in patients with LOS longer than 28 days (Fig. 1). Using a proportional subdistribution hazards model in which the occurrence of death was analyzed as a competing risk (Fine and Gray method) (9), the cumulative probability of carriage acquisition rose steadily as LOS increased, reaching 20% in patients still hospitalized in the ICU after 3 weeks (see Fig. S2 in the supplemental material). Most of the acquired HLAC-PE isolates were identified as E. cloacae
1884 aac.asm.org
(40.2%), Citrobacter freundii (17.0%), and Hafnia alvei (12.5%) (see Table S1 in the supplemental material). Overall, 94.1% of HLAC-PE isolates were susceptible to cefepime, while all remained susceptible to imipenem (see Table S2 in the supplemental material). Patients with acquired carriage were more often admitted for surgical reasons, had higher simplified acute physiology scores II (SAPS II) at admission, required more life-sustaining therapies, and had prolonged LOS compared to those with at least one collected surveillance swab and no carriage throughout the ICU stay (n ⫽ 551) (Table 2). Antimicrobial exposure was measured between admission and the first positive swab in patients with acquired carriage and during the whole ICU stay (i.e., until discharge or death) in persistent noncarriers. A total of 104 patients (97.2%) with acquired carriage and 401 patients (72.3%) without acquisition received antimicrobials (P ⬍ 0.0001), with significant
Antimicrobial Agents and Chemotherapy
March 2016 Volume 60 Number 3
AmpC-Hyperproducing Enterobacteriaceae in ICU Patients
FIG 1 Observed rates of intestinal carriage of high-level AmpC cephalosporinase-producing Enterobacteriaceae isolates in critically ill patients according to their length of stay in the intensive care unit (days). P value for trend was ⬍0.0001 (chi-square test). Bars indicate 95% confidence intervals.
variations in cephalosporins and metronidazole exposure (66.4% versus 54.1% and 30.8% versus 20.5%, respectively; P ⫽ 0.02 for the two comparisons). The clinical characteristics in Table 2 associated with acquired colonization (i.e., yielding P values of ⬍0.20 by bivariate analysis) were entered into a multiple logistic regression model with carriage acquisition as the primary outcome. The potential impact of antimicrobial use was analyzed in the model by entering the cumulative duration of exposure for each class as a continuous variable. Potential explanatory variables were selected using a backward procedure until the best fitted model was reached according to the Akaike information criterion (10). The best model retained only ICU LOS (odds ratio [OR], 1.03 per day; 95% confidence interval [95% CI], 1.01 to 1.04; P ⬍ 0.001), the SAPS II value at admission (OR, 1.02 per point; 95% CI, 1.01 to 1.04; P ⫽ 0.02), and metronidazole use (OR, 1.09 per treatment day; 95% CI, 1.01 to 1.17; P ⫽ 0.02) as independently associated with acquired carriage (Table 3). Mechanical ventilation, although retained in this model, did not reach statistical significance (OR, 1.62; 95% CI, 0.99 to 2.14; P ⫽ 0.09). Cephalosporins use was not an independent predictor of HLAC-PE acquisition after adjustment on LOS and other covariables, including metronidazole exposure (Table 3; see also Fig. S3 in the supplemental material). A total of 126 patients (10.4%) developed at least one ICUacquired infection, mainly ventilator-associated pneumonia (see Table S3 in the supplemental material). HLAC-PE infections occurred in 20 carriers (same species isolated from carriage and clinical samples in all patients; median delay between documented carriage and infection, 3 [2 to 13] days) and 1 patient without documented intestinal colonization (15.3% versus 0.1%; P ⬍ 0.0001). Carbapenem use (including imipenem and meropenem) was measured between the first positive swab and ICU discharge or death in HLAC-PE carriers and during the whole ICU stay in noncarriers. HLAC-PE infections and HLAC-PE carriage without infection were associated with a dramatic increase in carbapenem exposure compared to a lack of carriage (174, 65, and 31 carbapenem days per 1,000 patient-days, respectively; P ⬍ 0.0001 for all comparisons) (Table 3). ICU mortality rates (overall, 19.9%) did not differ between carriers and noncarriers. The prevalence of HLAC-PE carriage ranged from 9% to 19%
March 2016 Volume 60 Number 3
in the few studies conducted in ICU patients (5–7), which is in line with the 10.8% overall rate observed in our work. However, the impact of LOS on the likelihood of carriage acquisition had not been previously investigated. Here, colonization with HLAC-PE was mostly ICU-acquired (82% of cases) and became increasingly prevalent as LOS increased—with a 3% increase in the odds of carriage for each additional day spent in the ICU—affecting up to one-third of patients with LOS longer than 28 days. A link between cephalosporin exposure and the acquisition of HLAC-PE carriage has been reported (7). Conversely, a previous work found no correlation between ICU-level volumes of beta-lactam consumption and the rate of HLAC-PE acquisition (6). Our results from a cohort heavily exposed to antimicrobials indicate that, at the patient level, LOS outweighs beta-lactam exposure—and especially cephalosporin exposure—in predicting HLAC-PE acquisition (Table 3). Of note, and contrary to ESBL-PE acquisition in ICU patients (6, 11), HLAC-PE acquisition mostly depends on mutant selection from the endogenous intestinal microbiota and not on cross-transmission (5). Antibiotic-related alterations of the anaerobic flora may ease the emergence of such mutants from subdominant, wild-type Enterobacteriaceae populations, as suggested by the marginal effect observed with metronidazole exposure. HLAC-PE infections occurred in only 15% of carriers; however, HLAC-PE carriage was associated with a significant increase in carbapenem exposure, even in the absence of infection. Given the low rate of ESBL-PE cocolonization, this result probably reflects the local policy of empirical carbapenem use when sepsis occurs in identified HLAC-PE carriers. Indeed, taking into account a documented carriage of multidrug-resistant pathogens is advocated when choosing the empirical therapy for ICU patients with proven or suspected severe sepsis (1, 12). Yet, carbapenem overuse in patients carrying ESC-resistant Enterobacteriaceae may promote the dissemination of carbapenem-resistant Gramnegative bacilli (13, 14), including carbapenemase-producing Enterobacteriaceae in ICUs with endemicity (15). Cefepime has been recently proposed as a safe carbapenem-sparing option for the treatment of HLAC-PE infection (16, 17) and warrants further evaluation in critically ill patients to reduce carbapenem consumption in the ICU.
Antimicrobial Agents and Chemotherapy
aac.asm.org
1885
Poignant et al.
TABLE 2 Characteristics associated with acquired carriage of high-level AmpC cephalosporinase-producing Enterobacteriaceae during the intensive care unit stay in patients not colonized at admission Intestinal carriage of HLAC-PE during the ICU stay Variablea
Acquisition (n ⫽ 107)
No acquisitionb (n ⫽ 551)
Type of ICU stay, no. (%) Medical Surgical
89 (83.2) 18 (16.8)
498 (90.4) 53 (9.6)
Median SAPS II at ICU admission (interquartile range)
49 (40–58)
42 (32–55)
0.0002
Main diagnoses of the ICU stay, no. (%) Sepsis Neurological Renal Cardiac Intestinal/hepatic Trauma
72 (67.3) 15 (14.0) 37 (34.6) 23 (21.5) 5 (4.7) 19 (17.7)
333 (60.4) 83 (15.1) 137 (24.9) 108 (19.6) 29 (5.3) 72 (13.1)
0.18 0.78 0.04 0.65 0.80 0.20
104 (97.2) 16 (14.9) 3 (3–6) 49 (45.8) 6 (4–9) 71 (66.4) 5 (3–9) 12 (11.2) 5 (3–7) 21 (19.6) 3 (1–3) 0 33 (30.8) 7 (5–10) 15 (14.0) 4 (2–6)
401 (72.3) 102 (18.5) 5 (3–8) 251 (45.5) 6 (4–8) 298 (54.1) 7 (4–9) 48 (8.7) 6 (3–9) 120 (21.8) 3 (2–4) 26 (4.7) 5 (2–9) 113 (20.5) 6 (3–8) 76 (13.8) 4 (3–7)
⬍0.0001 0.38 0.83 0.96 0.51 0.02 0.19 0.41 0.86 0.62 0.97 0.02 NA 0.02 0.13 0.95 0.28
ESBL-PE carriage, no. (%) At ICU admission Acquired in the ICU
3 (2.8) 6 (5.6)
16 (2.9) 15 (2.7)
0.95 0.12
Use of life-sustaining therapy during the ICU stay, no. (%) Mechanical ventilation Vasopressors Renal replacement therapy
96 (89.7) 74 (69.1) 22 (20.6)
409 (74.2) 308 (55.9) 62 (11.2)
⬍0.0001 0.01 0.008
Median length of ICU stay, days (interquartile range)
18 (10–30)
11 (7–17)
⬍0.0001
Antimicrobial exposure during the ICU stayc, no. (%) Antimicrobial, any Penicillins Median duration, days (interquartile range) Penicillin ⫹ beta-lactamase inhibitor associations Median duration, days (interquartile range) Third- and fourth-generations cephalosporins Median duration, days (interquartile range) Carbapenems Median duration, days (interquartile range) Aminoglycosides Median duration, days (interquartile range) Fluoroquinolones Median duration, days (interquartile range) Metronidazole Median duration, days (interquartile range) Glycopeptides Median duration, days (interquartile range)
P value 0.03
a
Age, gender, comorbidities, and history of previous hospitalization or surgery did not differ between patients with acquired carriage and noncarriers (data not shown). b Only patients with at least one surveillance swab collected during the ICU stay were included as comparators (527 patients not colonized at admission were discharged alive or died in the ICU before a first weekly surveillance swab was collected). c Between ICU admission and the first positive rectal swab in patients with acquired HLAC-PE carriage and during the whole ICU stay in noncarriers.
The single-center design represents the main limitation of this study. However, colonization pressure and cross-transmission appear to play a minor role in HLAC-PE acquisition (5), which suggests that the present results may not have been significantly impacted by our local ecology. Next, since HLAC-PE were identified using routine phenotypic methods and not molecular assays, we were unable to determine whether the HLAC phenotype resulted from the derepression of a chromosomal blaampC gene or from the acquisition of a plasmid-borne AmpC variant. Nevertheless, the available evidence suggests that the former mechanism accounted for most of the HLAC-PE isolates (2). Also, antimicro-
1886
aac.asm.org
bial exposure was measured for each class as the cumulative number of treatment days; therefore, the respective impact of each course could not be determined for patients with multiple courses of the same class during their ICU stay. Lastly, in our hospital, patients hospitalized in non-ICU wards are not routinely screened for HLAC-PE carriage. Thus, some patients transferred from wards and classified as noncarriers at ICU admission may have been transient carriers during their hospital stay. Likewise, data on previous HLAC-PE carriage or infections may have been missing for patients hospitalized in other hospitals within the year preceding ICU admission.
Antimicrobial Agents and Chemotherapy
March 2016 Volume 60 Number 3
AmpC-Hyperproducing Enterobacteriaceae in ICU Patients
TABLE 3 Acquired carriage of high-level AmpC cephalosporinase-producing Enterobacteriaceae during the intensive care unit stay in patients not colonized at admission: results of logistic regression analysesa Variable
Bivariate logistic regression, unadjusted OR (95% CI)
Multivariate logistic regression, adjusted OR (95% CI)
1.90 (1.06–3.40) 1.02 (1.01–1.03)
1.02 (1.01–1.04)
Type of ICU stay, surgical vs medical SAPS II at ICU admission, per point increase Main diagnoses of the ICU stay Sepsis Renal
1.35 (0.87–2.10) 1.60 (1.03–2.29)
Antimicrobial exposure during the ICU stay Third- and fourth-generations cephalosporins, per day Metronidazole, per day
1.03 (1.00–1.07) 1.02 (1.01–1.03)
Use of life-sustaining therapy during the ICU stay Mechanical ventilation Vasopressors Renal replacement therapy
1.08 (1.02–1.13) 1.77 (1.14–2.76) 2.04 (1.19–3.50)
1.62 (0.99–2.14)
Length of ICU stay, per day
1.02 (1.01–1.03)
1.03 (1.01–1.04)
a
1.09 (1.01–1.17)
OR, odds ratio; 65% CI, 95% confidence interval; ICU, intensive care unit; SAPS II, simplified acute physiology score II.
In conclusion, intestinal colonization with HLAC-PE is common in critically ill patients and is mainly acquired during the ICU stay. In this cohort with high antimicrobial exposure, LOS was the main predictor of carriage acquisition. Preserving the intestinal microbiota from antibiotic-related alterations appears essential to prevent the emergence of HLAC-PE.
10.
ACKNOWLEDGMENTS
11.
9.
F.B. received lecture fees from Novartis, conference invitations from Pfizer, and consulting fees from MSD. J.G. received a conference invitation from Pfizer. All other authors declare no potential conflicts of interest. 12.
REFERENCES 1. Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F, Nicolau DP, Paiva JA, Tumbarello M, Welte T, Wilcox M, Zahar JR, Poulakou G. 2015. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41:776 –795. http://dx.doi.org/10.1007/s00134-015-3719-z. 2. Ruppé E, Woerther PL, Barbier F. 2015. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care 5:21. http://dx.doi .org/10.1186/s13613-015-0061-0. 3. Jacoby GA. 2009. AmpC beta-lactamases. Clin Microbiol Rev 22:161– 182. http://dx.doi.org/10.1128/CMR.00036-08. 4. REA-Raisin Network. 2012. Surveillance of nosocomial infections in critically ill adult patients, France. www.cclinparisnord.org. Accessed 26 December 2014. 5. Grohs P, Podglajen I, Guerot E, Bellenfant F, Caumont-Prim A, Kac G, Tillecovidin B, Carbonnelle E, Chatellier G, Meyer G, Fagon JY, Gutmann L. 2014. Assessment of five screening strategies for optimal detection of carriers of third-generation cephalosporin-resistant Enterobacteriaceae in intensive care units using daily sampling. Clin Microbiol Infect 20:O879 –O886. http://dx.doi.org/10.1111/1469-0691.12663. 6. Thiebaut AC, Arlet G, Andremont A, Papy E, Sollet JP, BernedeBauduin C, Guillemot D, Schlemmer B. 2012. Variability of intestinal colonization with third-generation cephalosporin-resistant Enterobacteriaceae and antibiotic use in intensive care units. J Antimicrob Chemother 67:1525–1536. http://dx.doi.org/10.1093/jac/dks072. 7. Wendt C, Lin D, von Baum H. 2005. Risk factors for colonization with third-generation cephalosporin-resistant Enterobacteriaceae. Infection 33: 327–332. http://dx.doi.org/10.1007/s15010-005-5045-9. 8. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. 2008. The Strengthening the Reporting of Observational Stud-
March 2016 Volume 60 Number 3
13.
14.
15.
16.
17.
ies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344 –349. http://dx.doi.org/10.1016 /j.jclinepi.2007.11.008. Fine JP, Gray RG. 1999. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496 –509. http://dx.doi.org /10.1080/01621459.1999.10474144. Akaike H. 1974. A new look at statistical model identification. IEEE Trans Automat Contr 19:716 –722. http://dx.doi.org/10.1109/TAC.1974.1100705. Razazi K, Derde LP, Verachten M, Legrand P, Lesprit P, Brun-Buisson C. 2012. Clinical impact and risk factors for colonization with extendedspectrum beta-lactamase-producing bacteria in the intensive care unit. Intensive Care Med 38:1769 –1778. http://dx.doi.org/10.1007/s00134-012 -2675-0. Bretonnière C, Leone M, Milesi C, Allaouchiche B, Armand-Lefèvre L, Baldesi O, Bouadma L, Decré D, Figueiredo S, Gauzit R, Guéry B, Joram N, Jung B, Lasocki S, Lepape A, Lesage F, Pajot O, Philippart F, Souweine B, Tattevin P, Timsit JF, Vialet R, Zahar JR, Misset B, Bedos JP. 2015. Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric). Intensive Care Med 41:1181–1196. http://dx .doi.org/10.1007/s00134-015-3853-7. Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E, Bronchard R, Lepeule R, Lucet JC, El Mniai A, Wolff M, Montravers P, Plesiat P, Andremont A. 2013. Emergence of imipenemresistant Gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57:1488 –1495. http://dx.doi.org/10.1128 /AAC.01823-12. Zilberberg MD, Chen J, Mody SH, Ramsey AM, Shorr AF. 2010. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm Med 10:45. http://dx.doi.org/10.1186/1471-2466 -10-45. Papadimitriou-Olivgeris M, Marangos M, Fligou F, Christofidou M, Bartzavali C, Anastassiou ED, Filos KS. 2012. Risk factors for KPCproducing Klebsiella pneumoniae enteric colonization upon ICU admission. J Antimicrob Chemother 67:2976 –2981. http://dx.doi.org/10.1093 /jac/dks316. Siedner MJ, Galar A, Guzman-Suarez BB, Kubiak DW, Baghdady N, Ferraro MJ, Hooper DC, O’Brien TF, Marty FM. 2014. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis 58:1554 –1563. http://dx.doi.org/10.1093/cid /ciu182. Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, Cosgrove SE, Carroll KC. 2013. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis 57:781–788. http://dx.doi.org/10.1093/cid/cit395.
Antimicrobial Agents and Chemotherapy
aac.asm.org
1887
Risk Factors and Outcomes for Intestinal Carriage of AmpCHyperproducing Enterobacteriaceae in Intensive Care Unit Patients Simon Poignant,a Jérôme Guinard,b Aurélie Guigon,b Laurent Bret,b Didier-Marc Poisson,b Thierry Boulain,a François Barbiera Medical Intensive Care Unita and Department of Microbiology,b La Source Hospital, CHR Orléans, Orléans, France
In a cohort of 1,209 intensive care unit (ICU) patients, the prevalence of intestinal colonization with high-level expressed AmpC cephalosporinase-producing Enterobacteriaceae (HLAC-PE) rose steadily from 2% at admission to 30% in patients with lengths of stay (LOS) exceeding 4 weeks. In multivariate analysis, LOS was the main predictor of carriage acquisition after adjustment on antimicrobial exposure. HLAC-PE infection occurred in 15% of carriers. Carriage and infection were associated with a marked increase in carbapenem consumption.
T
he burden of expanded-spectrum cephalosporin (ESC) resistance in Enterobacteriaceae now represents a daily issue for the management of antimicrobial therapy in intensive care unit (ICU) patients (1, 2). Two distinct enzymatic mechanisms may be involved, namely, plasmid-borne extended-spectrum beta-lactamases (ESBL) and high-level expressed AmpC cephalosporinase (HLAC) (2). The HLAC phenotype results from the mutationinduced derepression of a normally low-level expressed chromosomal blaampC gene or, more rarely, from the horizontal transfer of a plasmid-borne AmpC variant (3). HLAC-producing Enterobacteriaceae (HLAC-PE) currently account for up to 50% of the ESCresistant Enterobacteriaceae responsible for ICU-acquired infections in settings with a high prevalence of ESBL-producing Enterobacteriaceae (ESBL-PE) (4). The intestinal microbiota forms the main reservoir of ESCresistant Enterobacteriaceae in ICU patients (5–7); however, the features of HLAC-PE carriage remain poorly described in this population. Our objectives were to identify the risk factors for HLAC-PE carriage and to appraise its clinical significance in terms of subsequent infections and carbapenem consumption in a large single-center cohort of critically ill patients. This retrospective study was conducted in the 18-bed medicalsurgical ICU of an 1,100-bed teaching hospital in France. During the 3-year study period (2008 to 2010), intestinal carriage of ESCresistant Enterobacteriaceae was routinely screened by rectal swabbing at admission and at weekly intervals afterwards as part of the institutional infection control policy, with implementation of isolation measures in identified carriers. Swabs were discharged in 1 ml of 0.9% saline, and 50 l of the suspension was subsequently plated on a selective medium for ESC-resistant Gram-negative bacilli (chromID ESBL; bioMérieux, Marcy-l’Étoile, France). After overnight incubation at 35°C, colonies were subcultured for identification (API 20E; bioMérieux) and susceptibility testing using the disk diffusion method on Mueller-Hinton agar plates (Bio-Rad, Marnes-la-Coquette, France), in accordance with the French Society of Microbiology guidelines (www.sfm-microbiologie.org). Third-generation cephalosporin -resistant Enterobacteriaceae isolates showing a synergy zone between ESC and clavulanate were categorized as ESBL-PE, while those without synergy and a ⱖ5-mm increase in the ESC inhibition diameter on cloxacillin-supplemented Mueller-Hinton agar (250 mg · ml⫺1) were categorized as HLAC-PE. Isolates producing ESBL and HLAC were classified as ESBL-PE. No
March 2016 Volume 60 Number 3
carbapenem-resistant Enterobacteriaceae were isolated in our ICU during the study period. Patients with a first ICU stay of more than 48 h were included. Variables in the tables were prospectively entered by attending ICU physicians into a local database used for diagnosis and procedures coding, surveillance of ICU-acquired infections, and monitoring of antimicrobial consumption. Additional data on antibiotic exposure were retrospectively extracted from the patients’ medical charts. HLAC-PE carriers were identified in the database of the bacteriology unit. Imported carriage was defined as a positive swab at ICU admission, while acquired carriage was defined as a positive surveillance swab in patients with a negative admission sample. Carriers were assumed to be colonized from the first positive swab to ICU discharge or death. The Institutional Review Board waived the requirement for informed consent (IRB 2015-02). Data are reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statements (8). Carriers and noncarriers were compared using the Student t test or the Mann-Whitney test for continuous variables and the Fischer exact test or the 2 test for categorical variables as appropriate. All tests were two-sided, and P values of ⬍0.05 were considered significant. Statistical analyses were carried out using R 2.15.1 (http://www.r-project.org). A total of 1,209 patients were included (Table 1; see also Fig. S1 in the supplemental material). None of them had a history of documented HLAC-PE infection during the hospital stay prior to ICU admission or during a previous hospital stay within the year preceding ICU admission. The 24 patients (2.0%) with imported HLAC-PE carriage had more frequent histories of chronic diseases, hospitalization within the previous year, and surgery within
Received 28 August 2015 Returned for modification 3 October 2015 Accepted 5 December 2015 Accepted manuscript posted online 14 December 2015 Citation Poignant S, Guinard J, Guigon A, Bret L, Poisson D-M, Boulain T, Barbier F. 2016. Risk factors and outcomes for intestinal carriage of AmpC-hyperproducing Enterobacteriaceae in intensive care unit patients. Antimicrob Agents Chemother 60:1883–1887. doi:10.1128/AAC.02101-15. Address correspondence to François Barbier, [email protected]. Supplemental material for this article may be found at http://dx.doi.org/10.1128 /AAC.02101-15. Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Antimicrobial Agents and Chemotherapy
aac.asm.org
1883
Poignant et al.
TABLE 1 Study population and factors associated with intestinal carriage of high-level AmpC cephalosporinase-producing Enterobacteriaceae at intensive care unit admissiona
Variable
All patients (n ⫽ 1,209)
Median age (interquartile range), yr Male gender, no. (%)
Intestinal carriage of HLAC-PE at ICU admission Carriers (n ⫽ 24)
Noncarriers (n ⫽ 1,185)
P value
63 (49–75) 763 (63.1)
68 (51–75) 19 (79.2)
63 (49–74) 744 (62.8)
0.23 0.13
Comorbidities, no. (%) Cardiac Respiratory End-stage renal disease Neurological Liver cirrhosis Malignancies Diabetes mellitus
579 (47.9) 296 (24.5) 23 (1.9) 66 (5.5) 37 (3.1) 123 (10.2) 223 (18.4)
15 (62.5) 12 (50.0) 0 3 (12.5) 2 (8.3) 5 (20.8) 8 (33.3)
564 (47.6) 284 (24.0) 23 (1.9) 63 (5.3) 35 (2.9) 118 (10.0) 215 (18.1)
0.15 0.007 1.0 0.15 0.16 0.07 0.06
Median McCabe score (interquartile range) Hospital stay within the previous year, no. (%) Surgery within the previous month, no. (%)
0 (0–0) 322 (26.6) 13 (1.1)
0 (0–1) 12 (50.0) 2 (8.3)
0 (0–0) 310 (26.2) 11 (1.0)
0.02 0.02 0.02
Admission, no. (%) Transfer Direct
379 (31.4) 830 (68.6)
15 (62.5) 9 (37.5)
364 (30.7) 821 (69.3)
0.002
Type of ICU stay, no. (%) Medical Surgical
1,091 (90.2) 118 (9.8)
20 (83.3) 4 (16.7)
1,071 (90.4) 114 (9.6)
0.28
Median SAPS II at ICU admission (interquartile range) ESBL-PE carriage at ICU admission, no. (%)
41 (29–53) 24 (2.0)
40 (31–43) 2 (8.3)
41 (29–53) 22 (1.8)
0.54 0.08
Main diagnoses of the ICU stay, no. (%) Sepsis Neurological Renal Cardiac Intestinal/hepatic Trauma
648 (53.6) 181 (15.0) 274 (22.7) 205 (16.9) 54 (4.5) 151 (12.5)
12 (50.0) 5 (20.8) 3 (12.5) 3 (12.5) 2 (8.3) 1 (4.2)
636 (53.7) 176 (14.8) 271 (22.9) 202 (17.0) 52 (4.4) 150 (12.6)
0.84 0.39 0.24 0.78 0.29 0.34
Use of life-sustaining therapies, no. (%) Mechanical ventilation Vasopressors Renal replacement therapy
806 (66.7) 580 (48.0) 125 (10.3)
16 (66.7) 7 (29.2) 1 (4.2)
790 (66.7) 573 (48.3) 124 (10.5)
1.0 0.07 0.5
a
HLAC-PE, high-level expressed AmpC-producing Enterobacteriaceae; ICU, intensive care unit; SAPS II, simplified acute physiology score II; ESBL-PE, extended-spectrum-lactamase-producing Enterobacteriaceae.
the previous month and were more often transferred from ward than patients not colonized at admission (Table 1). Enterobacter cloacae accounted for half of the imported HLAC-PE isolates (see Table S1 in the supplemental material). Among the 1,185 patients without HLAC-PE carriage at admission (median ICU length of stay [LOS], 7 days; interquartile range, 4 to 12 days), 107 (8.9%) became colonized during the ICU stay (acquisition rate, 7.7 per 1,000 patient-days). The rate of HLAC-PE carriage increased markedly over time, exceeding 30% in patients with LOS longer than 28 days (Fig. 1). Using a proportional subdistribution hazards model in which the occurrence of death was analyzed as a competing risk (Fine and Gray method) (9), the cumulative probability of carriage acquisition rose steadily as LOS increased, reaching 20% in patients still hospitalized in the ICU after 3 weeks (see Fig. S2 in the supplemental material). Most of the acquired HLAC-PE isolates were identified as E. cloacae
1884 aac.asm.org
(40.2%), Citrobacter freundii (17.0%), and Hafnia alvei (12.5%) (see Table S1 in the supplemental material). Overall, 94.1% of HLAC-PE isolates were susceptible to cefepime, while all remained susceptible to imipenem (see Table S2 in the supplemental material). Patients with acquired carriage were more often admitted for surgical reasons, had higher simplified acute physiology scores II (SAPS II) at admission, required more life-sustaining therapies, and had prolonged LOS compared to those with at least one collected surveillance swab and no carriage throughout the ICU stay (n ⫽ 551) (Table 2). Antimicrobial exposure was measured between admission and the first positive swab in patients with acquired carriage and during the whole ICU stay (i.e., until discharge or death) in persistent noncarriers. A total of 104 patients (97.2%) with acquired carriage and 401 patients (72.3%) without acquisition received antimicrobials (P ⬍ 0.0001), with significant
Antimicrobial Agents and Chemotherapy
March 2016 Volume 60 Number 3
AmpC-Hyperproducing Enterobacteriaceae in ICU Patients
FIG 1 Observed rates of intestinal carriage of high-level AmpC cephalosporinase-producing Enterobacteriaceae isolates in critically ill patients according to their length of stay in the intensive care unit (days). P value for trend was ⬍0.0001 (chi-square test). Bars indicate 95% confidence intervals.
variations in cephalosporins and metronidazole exposure (66.4% versus 54.1% and 30.8% versus 20.5%, respectively; P ⫽ 0.02 for the two comparisons). The clinical characteristics in Table 2 associated with acquired colonization (i.e., yielding P values of ⬍0.20 by bivariate analysis) were entered into a multiple logistic regression model with carriage acquisition as the primary outcome. The potential impact of antimicrobial use was analyzed in the model by entering the cumulative duration of exposure for each class as a continuous variable. Potential explanatory variables were selected using a backward procedure until the best fitted model was reached according to the Akaike information criterion (10). The best model retained only ICU LOS (odds ratio [OR], 1.03 per day; 95% confidence interval [95% CI], 1.01 to 1.04; P ⬍ 0.001), the SAPS II value at admission (OR, 1.02 per point; 95% CI, 1.01 to 1.04; P ⫽ 0.02), and metronidazole use (OR, 1.09 per treatment day; 95% CI, 1.01 to 1.17; P ⫽ 0.02) as independently associated with acquired carriage (Table 3). Mechanical ventilation, although retained in this model, did not reach statistical significance (OR, 1.62; 95% CI, 0.99 to 2.14; P ⫽ 0.09). Cephalosporins use was not an independent predictor of HLAC-PE acquisition after adjustment on LOS and other covariables, including metronidazole exposure (Table 3; see also Fig. S3 in the supplemental material). A total of 126 patients (10.4%) developed at least one ICUacquired infection, mainly ventilator-associated pneumonia (see Table S3 in the supplemental material). HLAC-PE infections occurred in 20 carriers (same species isolated from carriage and clinical samples in all patients; median delay between documented carriage and infection, 3 [2 to 13] days) and 1 patient without documented intestinal colonization (15.3% versus 0.1%; P ⬍ 0.0001). Carbapenem use (including imipenem and meropenem) was measured between the first positive swab and ICU discharge or death in HLAC-PE carriers and during the whole ICU stay in noncarriers. HLAC-PE infections and HLAC-PE carriage without infection were associated with a dramatic increase in carbapenem exposure compared to a lack of carriage (174, 65, and 31 carbapenem days per 1,000 patient-days, respectively; P ⬍ 0.0001 for all comparisons) (Table 3). ICU mortality rates (overall, 19.9%) did not differ between carriers and noncarriers. The prevalence of HLAC-PE carriage ranged from 9% to 19%
March 2016 Volume 60 Number 3
in the few studies conducted in ICU patients (5–7), which is in line with the 10.8% overall rate observed in our work. However, the impact of LOS on the likelihood of carriage acquisition had not been previously investigated. Here, colonization with HLAC-PE was mostly ICU-acquired (82% of cases) and became increasingly prevalent as LOS increased—with a 3% increase in the odds of carriage for each additional day spent in the ICU—affecting up to one-third of patients with LOS longer than 28 days. A link between cephalosporin exposure and the acquisition of HLAC-PE carriage has been reported (7). Conversely, a previous work found no correlation between ICU-level volumes of beta-lactam consumption and the rate of HLAC-PE acquisition (6). Our results from a cohort heavily exposed to antimicrobials indicate that, at the patient level, LOS outweighs beta-lactam exposure—and especially cephalosporin exposure—in predicting HLAC-PE acquisition (Table 3). Of note, and contrary to ESBL-PE acquisition in ICU patients (6, 11), HLAC-PE acquisition mostly depends on mutant selection from the endogenous intestinal microbiota and not on cross-transmission (5). Antibiotic-related alterations of the anaerobic flora may ease the emergence of such mutants from subdominant, wild-type Enterobacteriaceae populations, as suggested by the marginal effect observed with metronidazole exposure. HLAC-PE infections occurred in only 15% of carriers; however, HLAC-PE carriage was associated with a significant increase in carbapenem exposure, even in the absence of infection. Given the low rate of ESBL-PE cocolonization, this result probably reflects the local policy of empirical carbapenem use when sepsis occurs in identified HLAC-PE carriers. Indeed, taking into account a documented carriage of multidrug-resistant pathogens is advocated when choosing the empirical therapy for ICU patients with proven or suspected severe sepsis (1, 12). Yet, carbapenem overuse in patients carrying ESC-resistant Enterobacteriaceae may promote the dissemination of carbapenem-resistant Gramnegative bacilli (13, 14), including carbapenemase-producing Enterobacteriaceae in ICUs with endemicity (15). Cefepime has been recently proposed as a safe carbapenem-sparing option for the treatment of HLAC-PE infection (16, 17) and warrants further evaluation in critically ill patients to reduce carbapenem consumption in the ICU.
Antimicrobial Agents and Chemotherapy
aac.asm.org
1885
Poignant et al.
TABLE 2 Characteristics associated with acquired carriage of high-level AmpC cephalosporinase-producing Enterobacteriaceae during the intensive care unit stay in patients not colonized at admission Intestinal carriage of HLAC-PE during the ICU stay Variablea
Acquisition (n ⫽ 107)
No acquisitionb (n ⫽ 551)
Type of ICU stay, no. (%) Medical Surgical
89 (83.2) 18 (16.8)
498 (90.4) 53 (9.6)
Median SAPS II at ICU admission (interquartile range)
49 (40–58)
42 (32–55)
0.0002
Main diagnoses of the ICU stay, no. (%) Sepsis Neurological Renal Cardiac Intestinal/hepatic Trauma
72 (67.3) 15 (14.0) 37 (34.6) 23 (21.5) 5 (4.7) 19 (17.7)
333 (60.4) 83 (15.1) 137 (24.9) 108 (19.6) 29 (5.3) 72 (13.1)
0.18 0.78 0.04 0.65 0.80 0.20
104 (97.2) 16 (14.9) 3 (3–6) 49 (45.8) 6 (4–9) 71 (66.4) 5 (3–9) 12 (11.2) 5 (3–7) 21 (19.6) 3 (1–3) 0 33 (30.8) 7 (5–10) 15 (14.0) 4 (2–6)
401 (72.3) 102 (18.5) 5 (3–8) 251 (45.5) 6 (4–8) 298 (54.1) 7 (4–9) 48 (8.7) 6 (3–9) 120 (21.8) 3 (2–4) 26 (4.7) 5 (2–9) 113 (20.5) 6 (3–8) 76 (13.8) 4 (3–7)
⬍0.0001 0.38 0.83 0.96 0.51 0.02 0.19 0.41 0.86 0.62 0.97 0.02 NA 0.02 0.13 0.95 0.28
ESBL-PE carriage, no. (%) At ICU admission Acquired in the ICU
3 (2.8) 6 (5.6)
16 (2.9) 15 (2.7)
0.95 0.12
Use of life-sustaining therapy during the ICU stay, no. (%) Mechanical ventilation Vasopressors Renal replacement therapy
96 (89.7) 74 (69.1) 22 (20.6)
409 (74.2) 308 (55.9) 62 (11.2)
⬍0.0001 0.01 0.008
Median length of ICU stay, days (interquartile range)
18 (10–30)
11 (7–17)
⬍0.0001
Antimicrobial exposure during the ICU stayc, no. (%) Antimicrobial, any Penicillins Median duration, days (interquartile range) Penicillin ⫹ beta-lactamase inhibitor associations Median duration, days (interquartile range) Third- and fourth-generations cephalosporins Median duration, days (interquartile range) Carbapenems Median duration, days (interquartile range) Aminoglycosides Median duration, days (interquartile range) Fluoroquinolones Median duration, days (interquartile range) Metronidazole Median duration, days (interquartile range) Glycopeptides Median duration, days (interquartile range)
P value 0.03
a
Age, gender, comorbidities, and history of previous hospitalization or surgery did not differ between patients with acquired carriage and noncarriers (data not shown). b Only patients with at least one surveillance swab collected during the ICU stay were included as comparators (527 patients not colonized at admission were discharged alive or died in the ICU before a first weekly surveillance swab was collected). c Between ICU admission and the first positive rectal swab in patients with acquired HLAC-PE carriage and during the whole ICU stay in noncarriers.
The single-center design represents the main limitation of this study. However, colonization pressure and cross-transmission appear to play a minor role in HLAC-PE acquisition (5), which suggests that the present results may not have been significantly impacted by our local ecology. Next, since HLAC-PE were identified using routine phenotypic methods and not molecular assays, we were unable to determine whether the HLAC phenotype resulted from the derepression of a chromosomal blaampC gene or from the acquisition of a plasmid-borne AmpC variant. Nevertheless, the available evidence suggests that the former mechanism accounted for most of the HLAC-PE isolates (2). Also, antimicro-
1886
aac.asm.org
bial exposure was measured for each class as the cumulative number of treatment days; therefore, the respective impact of each course could not be determined for patients with multiple courses of the same class during their ICU stay. Lastly, in our hospital, patients hospitalized in non-ICU wards are not routinely screened for HLAC-PE carriage. Thus, some patients transferred from wards and classified as noncarriers at ICU admission may have been transient carriers during their hospital stay. Likewise, data on previous HLAC-PE carriage or infections may have been missing for patients hospitalized in other hospitals within the year preceding ICU admission.
Antimicrobial Agents and Chemotherapy
March 2016 Volume 60 Number 3
AmpC-Hyperproducing Enterobacteriaceae in ICU Patients
TABLE 3 Acquired carriage of high-level AmpC cephalosporinase-producing Enterobacteriaceae during the intensive care unit stay in patients not colonized at admission: results of logistic regression analysesa Variable
Bivariate logistic regression, unadjusted OR (95% CI)
Multivariate logistic regression, adjusted OR (95% CI)
1.90 (1.06–3.40) 1.02 (1.01–1.03)
1.02 (1.01–1.04)
Type of ICU stay, surgical vs medical SAPS II at ICU admission, per point increase Main diagnoses of the ICU stay Sepsis Renal
1.35 (0.87–2.10) 1.60 (1.03–2.29)
Antimicrobial exposure during the ICU stay Third- and fourth-generations cephalosporins, per day Metronidazole, per day
1.03 (1.00–1.07) 1.02 (1.01–1.03)
Use of life-sustaining therapy during the ICU stay Mechanical ventilation Vasopressors Renal replacement therapy
1.08 (1.02–1.13) 1.77 (1.14–2.76) 2.04 (1.19–3.50)
1.62 (0.99–2.14)
Length of ICU stay, per day
1.02 (1.01–1.03)
1.03 (1.01–1.04)
a
1.09 (1.01–1.17)
OR, odds ratio; 65% CI, 95% confidence interval; ICU, intensive care unit; SAPS II, simplified acute physiology score II.
In conclusion, intestinal colonization with HLAC-PE is common in critically ill patients and is mainly acquired during the ICU stay. In this cohort with high antimicrobial exposure, LOS was the main predictor of carriage acquisition. Preserving the intestinal microbiota from antibiotic-related alterations appears essential to prevent the emergence of HLAC-PE.
10.
ACKNOWLEDGMENTS
11.
9.
F.B. received lecture fees from Novartis, conference invitations from Pfizer, and consulting fees from MSD. J.G. received a conference invitation from Pfizer. All other authors declare no potential conflicts of interest. 12.
REFERENCES 1. Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F, Nicolau DP, Paiva JA, Tumbarello M, Welte T, Wilcox M, Zahar JR, Poulakou G. 2015. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41:776 –795. http://dx.doi.org/10.1007/s00134-015-3719-z. 2. Ruppé E, Woerther PL, Barbier F. 2015. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care 5:21. http://dx.doi .org/10.1186/s13613-015-0061-0. 3. Jacoby GA. 2009. AmpC beta-lactamases. Clin Microbiol Rev 22:161– 182. http://dx.doi.org/10.1128/CMR.00036-08. 4. REA-Raisin Network. 2012. Surveillance of nosocomial infections in critically ill adult patients, France. www.cclinparisnord.org. Accessed 26 December 2014. 5. Grohs P, Podglajen I, Guerot E, Bellenfant F, Caumont-Prim A, Kac G, Tillecovidin B, Carbonnelle E, Chatellier G, Meyer G, Fagon JY, Gutmann L. 2014. Assessment of five screening strategies for optimal detection of carriers of third-generation cephalosporin-resistant Enterobacteriaceae in intensive care units using daily sampling. Clin Microbiol Infect 20:O879 –O886. http://dx.doi.org/10.1111/1469-0691.12663. 6. Thiebaut AC, Arlet G, Andremont A, Papy E, Sollet JP, BernedeBauduin C, Guillemot D, Schlemmer B. 2012. Variability of intestinal colonization with third-generation cephalosporin-resistant Enterobacteriaceae and antibiotic use in intensive care units. J Antimicrob Chemother 67:1525–1536. http://dx.doi.org/10.1093/jac/dks072. 7. Wendt C, Lin D, von Baum H. 2005. Risk factors for colonization with third-generation cephalosporin-resistant Enterobacteriaceae. Infection 33: 327–332. http://dx.doi.org/10.1007/s15010-005-5045-9. 8. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. 2008. The Strengthening the Reporting of Observational Stud-
March 2016 Volume 60 Number 3
13.
14.
15.
16.
17.
ies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344 –349. http://dx.doi.org/10.1016 /j.jclinepi.2007.11.008. Fine JP, Gray RG. 1999. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496 –509. http://dx.doi.org /10.1080/01621459.1999.10474144. Akaike H. 1974. A new look at statistical model identification. IEEE Trans Automat Contr 19:716 –722. http://dx.doi.org/10.1109/TAC.1974.1100705. Razazi K, Derde LP, Verachten M, Legrand P, Lesprit P, Brun-Buisson C. 2012. Clinical impact and risk factors for colonization with extendedspectrum beta-lactamase-producing bacteria in the intensive care unit. Intensive Care Med 38:1769 –1778. http://dx.doi.org/10.1007/s00134-012 -2675-0. Bretonnière C, Leone M, Milesi C, Allaouchiche B, Armand-Lefèvre L, Baldesi O, Bouadma L, Decré D, Figueiredo S, Gauzit R, Guéry B, Joram N, Jung B, Lasocki S, Lepape A, Lesage F, Pajot O, Philippart F, Souweine B, Tattevin P, Timsit JF, Vialet R, Zahar JR, Misset B, Bedos JP. 2015. Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric). Intensive Care Med 41:1181–1196. http://dx .doi.org/10.1007/s00134-015-3853-7. Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E, Bronchard R, Lepeule R, Lucet JC, El Mniai A, Wolff M, Montravers P, Plesiat P, Andremont A. 2013. Emergence of imipenemresistant Gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57:1488 –1495. http://dx.doi.org/10.1128 /AAC.01823-12. Zilberberg MD, Chen J, Mody SH, Ramsey AM, Shorr AF. 2010. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm Med 10:45. http://dx.doi.org/10.1186/1471-2466 -10-45. Papadimitriou-Olivgeris M, Marangos M, Fligou F, Christofidou M, Bartzavali C, Anastassiou ED, Filos KS. 2012. Risk factors for KPCproducing Klebsiella pneumoniae enteric colonization upon ICU admission. J Antimicrob Chemother 67:2976 –2981. http://dx.doi.org/10.1093 /jac/dks316. Siedner MJ, Galar A, Guzman-Suarez BB, Kubiak DW, Baghdady N, Ferraro MJ, Hooper DC, O’Brien TF, Marty FM. 2014. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis 58:1554 –1563. http://dx.doi.org/10.1093/cid /ciu182. Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, Cosgrove SE, Carroll KC. 2013. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis 57:781–788. http://dx.doi.org/10.1093/cid/cit395.
Antimicrobial Agents and Chemotherapy
aac.asm.org
1887
